483
Bristol-Myers Squibb CompanyFDA 483 - Bristol-Myers Squibb Company - January 25, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Celgene Corporation's headquarters in Summit, NJ, revealed significant deficiencies in adverse drug experience reporting. The firm failed to report numerous serious and unexpected adverse drug experiences to the FDA within the required 15 calendar days. This included approximately 724 initial and follow-up reports submitted late between August 2015 and December 2016, with some delays extending over several years.
Open in Dashboard
ID · d9ab1e53-7ce9-4a8c-b38e-01f5e565a0ed